Kiromic BioPharma에 대한 매도 수량은 투자자에게 Kiromic BioPharma의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Kiromic BioPharma (OTC:KRBP) 주식, 공매도 수량 보고

Kiromic BioPharma

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Biotech

News

Legal

General

KRBP

사기 혐의로 51개월 징역형 선고 및 610만 달러 배상 명령받은 남성 라스베이거스에 거주하는 55세의 미칼라이 콘틸라이(Mykalai Kontilai)는 목요일에 장기 사기 계획에 연루된 혐의로 징역 51개월과 배상금으로 610만 달러를 지불하라는 선고를 받았다. 이전에 마이클 콘틸레(Michael Contile)로 알려진 콘틸라이는 콜렉터스 카페(Collector&#39;s Café)라고도 알려진 그의 회사인 콜렉터스 커피(Collector&#39;s Coffee Inc.)를 통해 투자 사기를 주도했다.

주간 금융 범죄: 콘틸라이에 51개월 형 선고, 키로믹은 중요 정보 미공개로 기소

KIROMIC BIOPHARMA INC by Kiromic BioPharma, Inc.

Kiromic BioPharma Inc

Rumors

Analyst Ratings

Trading Ideas

QUBT

Watching Quantum Computing; Traders Circulate Zacks Mentioned The Stock As A Buy

Citigroup analyst Steven Enders maintains Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) with a Buy and raises the price target from $4 to $5.

Price Target

EXFY

Citigroup Maintains Buy on Expensify, Raises Price Target to $5

Citigroup analyst Steven Enders maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Neutral and raises the price target from $64 to $73.

Citigroup Maintains Neutral on BlackLine, Raises Price Target to $73

WIIM

EWTX

Edgewise Therapeutics shares are trading higher after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.

CLVT

Clarivate shares are trading higher after the company announced a new $500 million share repurchase authorization.

LFST

LifeStance Health Group shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy.

Banco Macro shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Overweight.

RDDT

UPDATE: Reddit Report Of "Confidential Submission Of Draft Registration Statement Related To Proposed Public Offering" Was Reported December 15, 2021.; Co Says "This Is An Old Blog Post Since We're Obviously A Public Company Already. You Can See It Has Been Removed And Was An Error"

Citigroup analyst Jason Gursky maintains Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and raises the price target from $4.05 to $5.

Citigroup Maintains Buy on Planet Labs, Raises Price Target to $5

Cabaletta Bio's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NYSE">CABA</a>) short percent of float has risen 25.26% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 9.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cabaletta Bio Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cabaletta Bio has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cabaletta Bio's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cabaletta Bio's peer group average for short interest as a percentage of float is 8.59%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CABA

Peering Into Cabaletta Bio's Recent Short Interest

Rocket Lab USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NYSE">RKLB</a>) short percent of float has fallen 8.31% since its last report. The company recently reported that it has 49.28 million shares sold short, which is 13.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Rocket Lab USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Rocket Lab USA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Rocket Lab USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Rocket Lab USA's peer group average for short interest as a percentage of float is 2.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RKLB

(RKLB) - Analyzing Rocket Lab USA's Short Interest

Mobileye Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NYSE">MBLY</a>) short percent of float has fallen 3.8% since its last report. The company recently reported that it has 20.87 million shares sold short, which is 29.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mobileye Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mobileye Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mobileye Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mobileye Global's peer group average for short interest as a percentage of float is 6.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MBLY

Peering Into Mobileye Global's Recent Short Interest

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 30.12% on an annualized basis producing an average annual return of 43.71%. Currently, Viking Therapeutics has a market capitalization of $5.24 billion. 
Buying $100 In VKTX: If an investor had bought $100 of VKTX stock 5 years ago, it would be worth $596.07 today based on a price of $47.00 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VKTX

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) with a Buy and maintains $37 price target.

Reiteration

PHAR

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Morgan Stanley analyst Jorge Kuri upgrades Banco Macro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMA#NYSE">BMA</a>) from Underweight to Overweight and announces $12.5 price target.

Upgrades

Morgan Stanley Upgrades Banco Macro to Overweight, Announces $12.5 Price Target

Management

VLGEA

Village Super Market Appoints John J. Sumas As CEO; Nicholas J. Sumas Ii Appointed President & Chairman Of Board

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and maintains $34 price target.

VRDN

HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target

<a href="https://www.benzinga.com/24/11/42145521/netapp-analysts-raise-their-forecasts-after-strong-earnings">JPMorgan analyst Samik Chatterjee</a> upgraded the rating for NetApp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Neutral to Overweight, while raising the price target from $150 to $160.
The company's revenue growth is likely to accelerate, driven by higher IT budgets for data centers and storage infrastructure of Enterprises looking to leverage AI use cases, according to JPMorgan.
The NetApp Thesis: Apart from higher enterprise spending, the company is also poised to benefit from its continued share gains from the recent pace of innovation, Chatterjee said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"In addition to recent expansion in product portfolio via addition of C-series products, we expect more launches in relation to C-series products, Block storage (ASA products) as well as products based on disaggregated architecture, which will further enhance the already robust product portfolio and drive growth," the analyst wrote.
In late November, NetApp reported <a href="https://www.benzinga.com/24/11/42145521/netapp-analysts-raise-their-forecasts-after-strong-earnings">better-than-expected quarterly results</a>.
The company's revenue growth could accelerate closer to the mid-point or higher-end of the company's latest guidance range, Chatterjee added.
"With resilient gross margins and operating leverage, we expect the modest revenue growth acceleration to be sufficient in relation to driving more material upsides to earnings estimates," Chatterjee further stated.
NTAP Price Action: Shares of NetApphad risen by 2.41% to $124.90 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/42459200/2-ai-stocks-that-gap-and-crapped-for-a-dip-buying-opportunity">2 AI Stocks That Gap and Crapped for a Dip Buying Opportunity</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

NTAP

NetApp Is Poised For Revenue Growth Acceleration With AI Spending: Analyst

Stryker's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) short percent of float has fallen 11.36% since its last report. The company recently reported that it has 4.24 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Stryker Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Stryker has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Stryker's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stryker's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Stryker?

Verisk Analytics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NYSE">VRSK</a>) short percent of float has fallen 8.45% since its last report. The company recently reported that it has 2.43 million shares sold short, which is 1.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Verisk Analytics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Verisk Analytics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Verisk Analytics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Verisk Analytics's peer group average for short interest as a percentage of float is 3.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VRSK

Looking Into Verisk Analytics's Recent Short Interest

Kiromic Biopharma (KRBP) has released an update. Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Prom...

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic BioPharma files to withdraw registration statement

Kiromic Biopharma (KRBP) has issued an announcement. Kiromic BioPharma, Inc. is gearing up to share its corporate vision and strategy through a ser...

Kiromic Biopharma Outlines Vision in Stakeholder Meetings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the first quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -$1.00.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/krbp-stock-earnings-kiromic-biopharma-for-q1-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

The latest update is out from Kiromic Biopharma (KRBP). Kiromic BioPharma, Inc. has reached an agreement to transform $7.2 million of its high-inte...

Kiromic BioPharma's Strategic Financial Restructuring and Equity Shift

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the second quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/krbp-stock-earnings-kiromic-biopharma-for-q2-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024

Kiromic stock soars 65% on FDA fast track status for Deltacel

Kiromic BioPharma (KRBP) announced that it has entered into a settlement agreement with the U.S. SEC, resolving the previously disclosed SEC invest...

Kiromic BioPharma announces settlement of SEC investigation

The SEC announced that it has filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma (KRBP), Inc., its former CEO, M...

Comments

Kiromic BioPharma

매도 수량

Kiromic BioPharma (OTC:KRBP) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌